Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Delmer

Showing results (51-60 of 109) with videos related to

Pageof 11
Sort By:
Leukemia & Lymphoma|October 25, 2017
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcomeDaniela Steinbrecher, Billy Michael Chelliah Jebaraj, Christof Schneider, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 30, 2014
Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphomaChristophe Fruchart, Hervé Tilly, Franck Morschhauser, et al.
Blood|September 13, 2003
Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemiaOlivier Tournilhac, Bruno Cazin, Stéphane Leprètre, et al.
Blood|February 23, 2008
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trialsNathalie Mourad, Nicolas Mounier, Josette Brière, et al.
Haematologica|April 22, 2011
TET2 mutations in secondary acute myeloid leukemias: a French retrospective studyOlivier Kosmider, Eric Delabesse, Véronique Mansat de Mas, et al.
American Journal of Hematology|March 11, 2015
Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experienceLuc-Matthieu Fornecker, Thérèse Aurran-Schleinitz, Anne-Sophie Michallet, et al.
Haematologica|February 29, 2012
Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELAMarie-Hélène Delfau-Larue, Laurence de Leval, Bertrand Joly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulteEmmanuel Bachy, Pauline Brice, Richard Delarue, et al.
American Journal of Hematology|March 16, 2017
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) groupAnne-Sophie Michallet, Arnaud Campidelli, Helene Lequeu, et al.
Leukemia & Lymphoma|March 9, 2017
Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE studyDriss Chaoui, Sylvain Choquet, Laurence Sanhes, et al.
Pageof 11

Showing results (51-60 of 109) with videos related to

Sort By:
Pageof 11
Leukemia & Lymphoma|October 25, 2017
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcomeDaniela Steinbrecher, Billy Michael Chelliah Jebaraj, Christof Schneider, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 30, 2014
Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphomaChristophe Fruchart, Hervé Tilly, Franck Morschhauser, et al.
Blood|September 13, 2003
Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemiaOlivier Tournilhac, Bruno Cazin, Stéphane Leprètre, et al.
Blood|February 23, 2008
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trialsNathalie Mourad, Nicolas Mounier, Josette Brière, et al.
Haematologica|April 22, 2011
TET2 mutations in secondary acute myeloid leukemias: a French retrospective studyOlivier Kosmider, Eric Delabesse, Véronique Mansat de Mas, et al.
American Journal of Hematology|March 11, 2015
Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experienceLuc-Matthieu Fornecker, Thérèse Aurran-Schleinitz, Anne-Sophie Michallet, et al.
Haematologica|February 29, 2012
Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELAMarie-Hélène Delfau-Larue, Laurence de Leval, Bertrand Joly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulteEmmanuel Bachy, Pauline Brice, Richard Delarue, et al.
American Journal of Hematology|March 16, 2017
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) groupAnne-Sophie Michallet, Arnaud Campidelli, Helene Lequeu, et al.
Leukemia & Lymphoma|March 9, 2017
Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE studyDriss Chaoui, Sylvain Choquet, Laurence Sanhes, et al.
Pageof 11